Docoh
Loading...

SGLB Sigma Labs

Filed: 22 Apr 21, 4:05pm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2021

 

OR

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 001-38015

 

SIGMA LABS, INC.

(Exact name of registrant as specified in its charter)

 

NEVADA 27-1865814

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

3900 Paseo del Sol

Santa Fe, NM 87507

(Address of principal executive offices)

 

(505) 438-2576

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share SGLB The NASDAQ Stock Market LLC

Warrants to Purchase Common Stock,

par value $0.001 per share

 SGLBW The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes [X] No[  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer[  ]Accelerated Filer[  ]
Non-accelerated filer[X]Smaller reporting company[X]
Emerging growth company[  ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of April 20, 2021, the issuer had 10,493,598 shares of common stock outstanding.

 

 

 

 
 

 

SIGMA LABS, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION 
  
ITEM 1. FINANCIAL STATEMENTS3
  
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS16
  
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK19
  
ITEM 4. CONTROLS AND PROCEDURES19
  
PART II - OTHER INFORMATION 
  
ITEM 1. LEGAL PROCEEDINGS20
  
ITEM 1A. RISK FACTORS20
  
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.20
  
ITEM 3. DEFAULTS UPON SENIOR SECURITIES20
  
ITEM 4. MINE SAFETY DISCLOSURES20
  
ITEM 5. OTHER INFORMATION20
  
ITEM 6. EXHIBITS21
  
SIGNATURES22

 

2
 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

Sigma Labs, Inc.

Condensed Balance Sheets

(Unaudited)

 

  March 31, 2021  December 31, 2020 
       
ASSETS        
Current Assets:        
Cash $16,843,201  $3,700,814 
Accounts Receivable, net  388,050   331,562 
Inventory  747,780   659,651 
Prepaid Assets  135,453   90,735 
Total Current Assets  18,114,484   4,782,762 
         
Other Assets:        
Property and Equipment, net  128,318   138,626 
Intangible Assets, net  762,368   753,122 
Long-Term Prepaid Asset  26,000   26,000 
Total Other Assets  916,686   917,748 
         
TOTAL ASSETS $19,031,170  $5,700,510 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
Current Liabilities:        
Accounts Payable $280,437  $128,937 
Deferred Revenue  76,417   77,957 
Accrued Expenses  217,404   243,815 
Derivative Liability  4,905,927   - 
Total Current Liabilities  5,480,185   450,709 
         
Long-Term Liabilities        
Stock Appreciation Rights  93,525   48,341 
CARES Act Deferred Payroll Taxes  37,728   37,728 
Total Long-Term Liabilities  131,253   86,069 
TOTAL LIABILITIES  5,611,438   536,778 
         
Stockholders’ Equity        
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 465 and 715 issued and outstanding, respectively  1   1 
Common Stock, $0.001 par; 12,000,000 shares authorized; 10,493,598 and 5,995,320 issued and outstanding, respectively  10,494   5,995 
Additional Paid-In Capital  47,225,812   38,262,744 
Accumulated Deficit  (33,816,575)  (33,105,008)
Total Stockholders’ Equity  13,419,732   5,163,732 
         
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $19,031,170  $5,700,510 

 

See accompanying notes to condensed financial statements.

 

3
 

 

Sigma Labs, Inc.

Condensed Statements of Operations

(Unaudited)

 

  Three Months Ended 
  March 31, 2021  March 31, 2020 
       
REVENUES $458,140  $221,730 
         
COST OF REVENUE  128,331   244,703 
         
GROSS PROFIT  329,809   (22,973)
         
OPERATING EXPENSES:        
Salaries & Benefits  847,171   652,197 
Stock-Based Compensation  117,477   154,171 
Operating R&D Costs  196,340   53,689 
Investor & Public Relations  108,341   215,441 
Organization Costs  77,616   49,444 
Legal & Professional Service Fees  176,847   184,891 
Office Expenses  148,225   147,747 
Depreciation & Amortization  23,031   18,012 
Other Operating Expenses  86,356   84,049 
Total Operating Expenses  1,781,404   1,559,641 
         
LOSS FROM OPERATIONS  (1,451,595)  (1,582,614)
         
OTHER INCOME (EXPENSE)        
Interest Income  55   851 
Gain on Derivative Liability  802,285   - 
Exchange Rate Loss  (51)  (1,391)
Interest Expense  (1,353)  (431)
Total Other Income (Expense)  800,936   (971)
         
LOSS BEFORE PROVISION FOR INCOME TAXES  (650,659)  (1,583,585)
         
Provision for Income Taxes  -   - 
         
Net Loss $(650,659) $(1,583,585)
         
Preferred Dividends  (60,908)  (315,247)
         
Net Loss Applicable to Common Stockholders $(711,567) $(1,898,832)
         
Net Loss per Common Share - Basic and Diluted $(0.09) $(1.30)
         
Weighted Average Number of Shares Outstanding - Basic and Diluted  7,790,121   1,463,627 

 

See accompanying notes to condensed financial statements.

 

4
 

 

Sigma Labs, Inc.

Statement of Stockholders’ Equity

For The Quarters Ended March 31, 2021 and March 31, 2020

(Unaudited)

 

  Preferred Stock  Common Stock  Additional       
  Shares Outstanding  Preferred Stock  Shares Outstanding  Common Stock  Paid-in Capital  Accumulated Deficit  Total 
Balances,
December 31, 2020
  715  $1   5,995,320  $5,995  $38,262,744  $(33,105,008) $5,163,732 
                             
Net Loss  -   -   -   -   -   (650,659)  (650,659)
Common Shares Sold in Public Offerings  -   -   3,901,783   3,902   14,865,997   -   14,869,899 
Derivative Liability Value on Issuance date  -   -   -   -   (5,708,212)  -   (5,708,212)
Common Shares issued for Exercise of Warrants  -   -   475,995   476   1,135,534   -   1,136,010 
Preferred Stock Dividends  -   -   19,000   19   60,889   (60,908)  - 
Common Shares Issued for Conversion of Preferred Shares  (250)  -   100,000   100   (100)  -   - 
Common Shares Issued for Third Party Services  -   -   1,500   2   30,979   -   30,981 
Stock Options Issued to Directors for Services  -   -   -   -   61,471   -   61,471 
Stock Options Awarded to Employees  -   -   -   -   117,477   -   117,477 
Offering Costs  -   -   -   -   (1,600,967)  -   (1,600,967)
                             
Balances, March 31, 2021  465  $1   10,493,598  $10,494  $47,225,812  $(33,816,575) $13,419,732 

 

  Preferred Stock  Common Stock  Additional       
  Shares Outstanding  Preferred Stock  Shares Outstanding  Common Stock  Paid-in Capital  Accumulated Deficit  Total 
Balances, December 31, 2019  -  $-   1,403,759  $1,404  $26,746,439  $(26,095,594) $652,249 
                             
Net Loss  -   -   -   -   -   (1,583,585)  (1,583,585)
Preferred Shares Sold in Private Offering  1,973   3   -   -   2,099,997   -   2,100,000 
Preferred Stock Dividends  -   -   86,801   87   315,160   (315,247)  - 
Common Shares issued for Conversion of Preferred Shares  (1,107)  (2)  321,517   321   (319)  -   - 
Preferred Shares issued for Exercise of Preferred Warrants  512   1   -   -   499,199   -   499,200 
Securities Issued for Third Party Services  -   -   2,500   3   39,615   -   39,618 
Stock Options Awarded to Employees  -   -   -   -   154,170   -   154,170 
Offering Costs                  (428,876)  -   (428,876)
Issuance of Fractional Shares from Reverse Split  -   -   3,257   3   (3)  -   - 
                             
Balances, March 31, 2020  1,378  $2   1,817,834  $1,818  $29,425,382  $(27,994,426) $1,432,776 

 

See accompanying notes to condensed financial statements.

 

5
 

 

Sigma Labs, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

  Three Months Ended 
  March 31, 2021  March 31, 2020 
OPERATING ACTIVITIES        
Net Loss $(650,659) $(1,583,585)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:        
Noncash Expenses:        
Depreciation and Amortization  23,031   18,012 
Gain on Derivative Liability  (802,285)  - 
Stock Based Compensation Employees  117,477   154,171 
Stock Based Compensation – Third Party Services  30,981   39,618 
Stock Based Compensation - Directors  61,471   - 
Change in assets and liabilities:        
Accounts Receivable  (56,488)  (63,885)
Inventory  (88,129)  92,915 
Prepaid Assets  (44,718)  63,006 
Accounts Payable  151,500   (243,000)
Deferred Revenue  (1,540)  (45,330)
Accrued Expenses  (26,411)  42,383 
Long-term portion of Stock Appreciation Rights  45,184   - 
NET CASH USED IN OPERATING ACTIVITIES  (1,240,586)  (1,525,696)
         
INVESTING ACTIVITIES        
Purchase of Property and Equipment  (5,350)  (11,474)
Purchase of Intangible Assets  (16,619)  (39,055)
NET CASH USED IN INVESTING ACTIVITIES  (21,969)  (50,529)
         
FINANCING ACTIVITIES        
Gross Proceeds from Public and Private Issuances of Securities  14,869,899   2,100,000 
Less Offering Costs  (1,600,967)  (428,876)
Payment of Note Payable  -   (50,000)
Proceeds from Exercise of Warrants  1,136,010   499,200 
NET CASH PROVIDED BY FINANCING ACTIVITIES  14,404,942   2,120,324 
         
NET CHANGE IN CASH FOR PERIOD  13,142,387   544,099 
         
CASH AT BEGINNING OF PERIOD  3,700,814   86,919 
         
CASH AT END OF PERIOD $16,843,201  $631,018 
         
Supplemental Disclosures:        
Noncash investing and financing activities disclosure:        

Issuance of Common Shares for Preferred Dividends

 60,908   

315,247

 
Other noncash operating activities disclosure:        

Issuance of Securities for Services

  92,452   

39,618

 
Disclosure of cash paid for:        
Interest $

1,353

  $1,458 
Income Taxes $-  $- 

 

See accompanying notes to condensed financial statements.

 

6
 

 

SIGMA LABS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

 

NOTE 1 - Summary of Significant Accounting Policies

 

Nature of Business -Sigma Labs, Inc., formerly named Framewaves, Inc., a Nevada corporation, was founded by a group of scientists, engineers and businessmen to develop and commercialize novel and unique manufacturing and materials technologies. Sigma believes that some of these technologies will fundamentally redefine conventional quality assurance and process control practices by embedding them into the manufacturing processes in real time, enabling process intervention and ultimately leading to closed loop process control. The Company anticipates that its core technologies will allow its clientele to combine advanced manufacturing quality assurance and process control protocols with novel materials to achieve breakthrough product potential in many industries including aerospace, defense, oil and gas, bio-medical, and power generation. The terms the “Company,” “Sigma,” “we,” “us” and “our” refer to Sigma Labs, Inc.

 

Basis of Presentation - The accompanying financial statements have been prepared by the Company in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2021 and 2020 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. The Company suggests these condensed financial statements be read in conjunction with the December 31, 2020 audited financial statements and notes thereto included in the Company’s Form 10-K. The results of operations for the periods ended March 31, 2021 and 2020 are not necessarily indicative of the operating results for the full year.

 

Reclassification - Certain amounts in prior-period financial statements have been reclassified for comparative purposes to conform to presentation in the current-period financial statements.

 

Fair Value of Financial Instruments - The Company applies ASC 820, “Fair Value Measurements.” This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

 Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
   
 Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
   
 Level 3 - inputs to valuation methodology are unobservable and significant to the fair measurement.

 

7
 

 

The carrying amounts reported in the balance sheets for the cash and cash equivalents, receivables, accounts payable, and accrued liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest.

 

The Company does not use derivative instruments for hedging of market risk or for trading or speculative purposes. The derivative warrant liability at March 31, 2021 results from the issuance of warrants to purchase an aggregate of 2,190,000 shares of common stock issued in a private placement which closed concurrently with a registered direct offering of our common stock on March 26, 2021. The warrants will be exercisable commencing on the date the Company obtains stockholder approval to increase its authorized common shares from 12,000,000 to 24,000,000 (“the Initial Exercise Date”) and will expire two years after the initial exercise date.

 

Pursuant to ASC 815-40-25-10, because the Company does not currently have sufficient authorized and unissued shares of common stock available to settle the warrants, such warrants are accounted for as a derivative liability until such time as the Company receives the foregoing stockholder approval to increase its authorized shares. The Company has called a Special Stockholders’ Meeting (“the Special Meeting”) to be held on May 24, 2021 where it will seek such approval. Upon receiving approval, the Company will reclassify the warrant liability to equity pursuant to ASC 815.40.35.8. However, there can be no guarantee that such approval will be received, and in the event that stockholder approval is not received, the Company will continue to account for the outstanding warrants as a liability. In addition, the Company will be required to call a meeting of stockholders every 75 days after the Special Meeting to seek approval of the increase in authorized shares to not be in breach of the Securities Purchase Agreement.

 

The fair value of the warrant liability measured on a recurring basis is as follows:

 

  March 31, 2021  Date of Issuance March 26, 2021 
  Fair Value  Input Level  Fair Value  Input Level 
                 
Derivative liability - Warrants $4,905,927   Level 3  $5,708,212   Level 3 

 

The following table presents a reconciliation of the derivative liability measured at fair value on a recurring basis using significant unobservable input (Level 3):

 

  Warrants 
Fair Value on Issuance Date $5,708,212 
Change in fair value  (802,285)
Fair value on March 31, 2021 $4,905,927 

 

Loss Per Share – The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with ASC Topic No. 260, “Earnings Per Share.” Shares underlying the Companies outstanding warrants, options and preferred shares were excluded due to the anti-dilutive effect they would have on the computation. At March 31, 2021 and 2020, the Company had the following common shares underlying these instruments:

 

  Three Months Ended March 31, 
  2021  2020 
Warrants  1,797,931   1,244,712 
Preferred Stock Warrants  -   2,996,713 
Stock Options  856,082   159,637 
Preferred Stock  124,483   624,412 
Total Underlying Common Shares  2,778,496   5,025,474 

 

8
 

 

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended March 31, 2021 and 2020:

 

  Three Months Ended March 31 
  2021  2020 
       
Net Loss per Common Share - Basic and Diluted $(0.09 $(1.30)
Loss from continuing        
Operations available to        
Common stockholders (numerator) $(711,567 $(1,898,832)
         
Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)  7,790,121   1,463,627 

 

Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated by management. Significant accounting estimates that may materially change in the near future are impairment of long-lived assets, values of stock compensation awards and stock equivalents granted as offering costs, and allowance for bad debts and inventory obsolescence.

 

NOTE 2 – Inventory

 

At March 31, 2021 and December 31, 2020, the Company’s inventory was comprised of:

 

  March 31, 2021  December 31, 2020 
Raw Materials $328,878  $309,305 
Work in Process  188,466   175,884 
Finished Goods  230,436   174,462 
Total Inventory $747,780  $659,651 

 

NOTE 3 – Deferral of Social Security Tax Payments

 

Pursuant to sections 2302(a)(1) and (a)(2) of the CARES Act, the Company has elected to defer payments of its share of Social Security tax due during the “payroll tax deferral period”. The payroll tax deferral period began on March 27, 2020 and ends December 31, 2020. At March 31, 2021, the total amount of such deferral was $75,455. Per the terms of the deferral program, 50% of the deferred amount is due on December 31, 2021, and the remaining 50% is due on December 31, 2022 at 0% interest.

 

9
 

 

NOTE 4 - Derivative Liability

 

On March 26, 2021, the Company issued warrants to purchase an aggregate of 2,190,000 shares of common stock to holders in a private placement concurrently with a registered direct offering of 2,190,000 shares of its common stock. The warrants entitle the holders to purchase one share of our common stock at an exercise price equal to $4.32 per share commencing on the date the Company receives stockholder approval to increase its authorized common shares from 12,000,000 to 24,000,000 (the “Initial Exercise Date”) and will expire two years from the Initial Exercise Date. The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the registered direct offering. Management also determined that the Company currently does not have sufficient authorized and unissued shares to settle the warrants, and as such required classification as a liability pursuant to ASC 815 “Derivative Instruments and Hedging”. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations.

 

The Company has called a Special Stockholders’ Meeting (the “Special Meeting”) for May 24, 2021, where it will seek stockholder approval to increase its authorized shares. Upon such approval, the Company will reclassify the warrant liability to equity pursuant to ASC 815-40-35-8. However, in the event that the Company does not receive stockholder approval to increase its authorized shares, the Company will continue to account for the outstanding warrants as a derivative liability and will be required to call a meeting of stockholders every 75 days after the Special Meeting to seek approval of the increase in authorized shares to not be in breach of the Securities Purchase Agreement.

 

The fair value of the derivative liability presented below was measured using the Black Scholes valuation model. Significant inputs into the model for the three months ended March 31, 2021 are as follows:

 

  March 31, 2021 
Dividend yield  0.00%
Risk-free interest rate  0.7%
Expected volatility  121.2 % - 121.7%
Expected life (in years)  2 

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

  Warrants  Fair Value    
Warrant Liability Outstanding  per Share  Fair Value 
Fair Value at initial measurement date of March 26, 2021  2,190,000  $2.61  $5,708,212 
(Gain) on change in Fair Value of warrant liability          (802,285)
Fair Value as of March 31, 2021  2,190,000  $2.24  $4,905,927 

 

The Company has presented the fair value measurement as a Level 3 measurement, relying on unobservable inputs reflecting management’s assumptions. Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity and may be more sensitive to fluctuations in stock prices, volatility rates and U.S. Treasury Bond rates and could have a material impact on future fair value measurements.

 

The Company uses the Black Scholes model, based on the adjusted historical volatility rates for fair value measurements through the date of Shareholder Approval. Management has determined the Black Scholes model to be the most reliable and least volatile determinate of the current fair value of the warrants. It is the Company’s expectation to maximize on all observable market inputs for the warrants and calibrate the model to incorporate relevant observable market data into the fair value measurement at each future measurement date, if applicable.

 

During the three months ended March 31, 2021, the company recognized a gain of $802,285 on the change in fair value of warrants.

 

10
 

 

NOTE 5 - Stockholders’ Equity

 

Common Stock

 

In January 2021, the Company closed a public offering of its securities in which it issued 1,711,783 shares of common stock at $3.00 per share, resulting in net proceeds of approximately $4,532,445 after deducting underwriting commissions and other offering expenses payable by the Company. Pursuant to the Underwriting Agreement, the Company also issued to the Underwriter or its designee warrants to purchase 136,943 shares of common stock. Such warrants have a term of five years and an exercise price of $3.75 per share.

 

In February 2021, the Company issued 263,200 shares of common stock pursuant to the exercise of warrants issued in our January 2020 private placement.

 

In March 2021, the Company issued 119,000 shares of common stock in exchange for the conversion of 250 shares of Series D Convertible Preferred Stock, including 19,000 shares of common stock as in-kind payment of preferred stock dividends. Also in March 2021, the company issued 191,204 shares of common stock pursuant to the exercise of warrants issued in our April 2020 offering, and 21,591 shares of common stock issued pursuant to the cashless exercise of placement agent warrants.

 

In March 2021, the Company closed a public offering of its securities in which it issued 2,190,000 shares of common stock at $4.445 per share, resulting in net proceeds to the Company of approximately $8,736,487 after deducting placement agent commissions and other offering costs payable by the Company. Pursuant to the Purchase Agreement, the purchasers severally agreed to vote the shares of common stock purchased under the Purchase Agreement in favor of any resolution presented to the stockholders of the Company for the purpose of obtaining approval of an increase in the authorized shares of the Company’s Common Stock from 12,000,000 to 24,000,000 shares (“Stockholder Approval”). In a concurrent private placement under the Purchase Agreement, the Company issued to the purchasers warrants to purchase an aggregate of 2,190,000 shares of Common Stock at an exercise price of $4.32 per share. Each Warrant will be exercisable commencing on the date the Company obtains Stockholder Approval and will expire two years after the initial exercise date. The Company also issued to designees of the Placement Agent warrants to purchase up to 175,200 shares of Common Stock (the “Placement Agent Warrants”) constituting 8% of the aggregate number of shares of Common Stock sold in the Registered Offering, The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants have an exercise price equal to 125% of the offering price per share (or $5.55625 per share). Upon any exercise of the Warrants for cash, we have also agreed to pay the Placement Agent warrants to purchase 8.0% of the number of shares of our Common Stock issued upon the cash exercise of the Warrants.

 

In March 2021, Company issued 1,500 shares of common stock valued at $4.99 per share to CorProminence, an investor relations firm previously engaged by the Company as partial compensation for services previously rendered.

 

In the first quarter of 2020, the Company issued 408,318 shares of common stock in exchange for the conversion of 1,107 shares of Series D Convertible Preferred stock, including 86,801 shares of common stock as in-kind payment of preferred stock dividends.

 

In February 2020, the Company issued 2,500 shares of common stock valued at $8.70 per share to MHZCI, LLC, an investor relations firm engaged by the Company, as partial compensation for services to be rendered.

 

11
 

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock, $0.001 par value. 465 and 1,378 shares of preferred stock were issued and outstanding at March 31, 2021 and 2020, respectively.

 

In January 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the “Institutional Private Placement”). Pursuant to the SPA, the Company issued and sold 1,640 shares of the Company’s newly created Series D Convertible Preferred Stock (the “Series D Preferred Stock”). Under the Certificate of Designations for the Series D Preferred Stock, the Series D Preferred Stock has an initial stated value of $1,000 per share (the “Stated Value”). Dividends accrue at a dividend rate of 9% per annum (subject to increase upon the occurrence (and during the continuance) of certain triggering events described therein) and, on a monthly basis, shall be payable in kind by the increase of the Stated Value of the Series D Preferred Shares by said amount. The holders of the Series D Preferred Shares have the right at any time to convert all or a portion of the Series D Preferred Shares (including, without limitation, accrued and unpaid dividends and make-whole dividends through the third anniversary of the closing date) into shares of the Company’s Common Stock at the conversion price then in effect, which is $2.50 (subject to adjustment for stock splits, dividends, recapitalizations and similar events and full ratchet price protection). In addition, a holder may at any time, alternatively, convert all, or any part, of its Series D Preferred Shares at an alternative conversion price, which equals the lower of the applicable conversion price then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume weighted average price (“VWAP”) of the Common Stock for a five (5) trading day period prior to such conversion. Upon the occurrence of certain triggering events, described in the Certificate of Designations, including, but not limited to payment defaults, breaches of transaction documents, failure to maintain listing on the Nasdaq Capital Market, and other defaults set forth therein, the Series D Preferred Shares would become subject to redemption, at the option of a holder, at a 125% premium to the underlying value of the Series D Preferred Shares being redeemed.

 

At March 31, 2021 there were 132 shares of Series D Convertible Preferred stock outstanding, which if converted at the Conversion Price of $2.50 as of March 31, 2021, including the make-whole dividends, would result in the issuance of 62,832 shares of common stock.

 

Concurrent with the Institutional Private Placement, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain of its directors and the Company’s largest shareholder (the “Other Private Placement”). Pursuant to the SPA, the Company issued and sold 333 shares of the Company’s newly created Series E Convertible Preferred Stock (the “Series E Preferred Stock”). Dividends accrue at a dividend rate of 9% per annum and, on a monthly basis, shall be payable in kind by the increase of the Stated Value of the Series E Preferred Shares by said amount. The Series E Preferred Stock is initially convertible into 48,544 shares of Common Stock,

 

At March 31, 2021, all of the issued Series E Convertible Preferred Stock was outstanding, which if converted as of March 31, 2021, including the make-whole dividends, would result in the issuance of 61,651 shares of common stock.

 

12
 

 

Stock Options

 

As of March 31, 2021, an aggregate of 9,681 shares of common stock were reserved for future issuance under the 2013 Plan.

 

In January 2021, the Company granted options to purchase 96,000 shares of common stock to its directors and an option to purchase 24,000 shares of common stock to a consultant as partial compensation for services to be rendered. The options have a strike price of $3.13 and vest equally over twelve months beginning January 2021.

 

During the three months ended March 31, 2021, the Company granted five employees options to purchase up to 20,500 shares of common stock in connection with their employment. The options have strike prices equal to the closing price of our common stock on each of the grant dates, and will vest in equal installments on the first through third anniversaries of the grant dates, provided that the employees remain employed by the Company on such dates.

 

In January 2021, the Company granted a consultant an option to purchase 1,000 shares of common stock for services to be rendered. The option has a strike price of $3.52 and will vest on June 30, 2021, provided that the consultant remains a service provider to the Company as of such date,

 

In February 2021, the Company granted a consultant an option to purchase 1,572 shares of common stock for services rendered. The option has a strike price of $3.66 and is fully vested.

 

During the three months ended March 31, 2020, the Company granted options to purchase 8,100 shares of common stock to Iron Dome Ventures, LLC as partial compensation for investor relations services to be rendered. The option vests equally over nine months beginning February 2020.

 

The Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s stock on the dates of grant. Stock options are typically granted throughout the year and generally vest over four years of service and expire five years from the date of the award, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the requisite service period for each stock option award.

 

Total share-based compensation expense included in the statements of operations for the three months ended March 31, 2021 and 2020 is $117,477 and $154,170, all of which is related to stock options.

 

The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the three months ended March 31, 2021 and the year ended December 31, 2020:

 

Assumptions:

 

  2021  2020 
Dividend yield  0.00%  0.00%
Risk-free interest rate  0.19-0.22%  0.19-0.50%
Expected volatility  116.8-117.2%  116.0-117.0%
Expected life (in years)  5   5 

 

13
 

 

Option activity for the three months ended March 31, 2021 and the year ended December 31, 2020 was as follows:

 

  Options  Weighted Average Exercise Price ($)  Weighted Average Remaining Contractual Life (Yrs.)  Aggregate Intrinsic Value ($) 
             
Options outstanding at December 31, 2019  180,912   1.81   5.09   25,988 
Granted  579,998   2.55   4.57   - 
Exercised  -   -   -   - 
Forfeited or cancelled  (47,900)  22.62   -   - 
Options outstanding at December 31, 2020  713,010   5.15   4.40   477,802 
Granted  143,072   3.21   4.77   - 
Exercised  -   -   -   - 
Forfeited or cancelled  -   -   -   - 
Options outstanding March 31, 2021  856,082   4.82   4.26   746,906 
Options expected to vest in the future as of March 31, 2021  439,611   3.73   4.40   - 
Options exercisable at March 31, 2021  416,471   5.98   4.10   - 
Options vested, exercisable, and options expected to vest at March 31, 2021  856,082   4.82   4.26   746,906 

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the $3.72 closing price of our Common Stock on March 31, 2021. At March 31, 2021, 718,070 option grants have an exercise price currently below $3.72.

 

At March 31, 2021, there was $1,198,573 of unrecognized share-based compensation expense related to unvested share options with a weighted average remaining recognition period of 2.84 years.

 

Stock Appreciation Rights

 

On June 23, 2020, the board of directors (the “Board”) of the Company adopted the Sigma Labs, Inc. 2020 Stock Appreciation Rights Plan (the “Plan”). The purposes of the Plan are to: (i) enable the Company to attract and retain the types of employees, consultants, and directors (collectively, “Service Providers”) who will contribute to the Company’s long-range success; (ii) provide incentives that align the interests of Service Providers with those of the shareholders of the Company; and (iii) promote the success of the Company’s business. The Plan provides for incentive awards that are only made in the form of stock appreciation rights payable in cash (“SARs”). No shares of common stock were reserved in connection with the adoption of the Plan since no shares will be issued pursuant to the Plan.

 

SARs may be granted to any Service Provider. A SAR is the right to receive an amount equal to the Spread with respect to a share of the Company’s common stock (“Share”) upon the exercise of the SAR. The “Spread” is the difference between the exercise price per share specified in a SAR agreement on the date of grant and the fair market value per share on the date of exercise of the SAR. The exercise price per share will not be less than 100% of the fair market value of a Share on the date of grant of the SAR. The administrator of the Plan will have the authority to, among other things, prescribe the terms and conditions of each SAR, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the SAR Agreement relating to such grant.

 

On June 23, 2020, the Company granted, pursuant to the Plan, (i) 60,094 SARs to its President and Chief Executive Officer, (ii) 12,019 SARs to its Vice President of Business Development, (iii) 24,038 SARs to its Chief Technology Officer, and (iv) 18,028 SARs to its Chief Financial Officer. The exercise price of each such SAR is $2.63, which was the closing price of the Company’s common stock on the date of grant. Such SARs expire on the fifth anniversary of the grant date and may be settled only in cash. Additionally, each such SAR will vest and become exercisable in three equal (as closely as possible) installments on each of the first, second and third anniversaries of the grant date, subject, in each case, to the applicable SAR holder being in the continuous employ of the Company on the applicable vesting date, and, in the event of a Change in Control (as defined in the Plan), will become immediately vested and exercisable as long as the applicable holder is in the Company’s employ immediately prior to the Change in Control, and will otherwise be on such other terms set forth in the form of Stock Appreciation Rights Agreement. On November 19, 2020, we granted 13,500 SARs to a consultant as partial compensation for services pursuant to the consulting agreement.

 

The Company recognizes compensation expense and a corresponding liability for the fair value of the SARs over the requisite service period for each SAR award. The SAR’s are revalued at each reporting date in accordance with ASC 718 “Compensation-Stock Compensation”, and any changes in fair value are reflected in income as of the applicable reporting date.

 

14
 

 

The fair value of SAR awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the three months ended March 31, 2021 and the year ended December 31, 2020:

 

Assumptions:

 

  2021  2020 
Dividend yield  0.00%   0.00-%
Risk-free interest rate  0.19-0.22%   0.19-0.22% 
Expected volatility  116.2%-116,8%   116.2-116.8% 
Expected life (in years)  5   5 

 

SARs activity for the three months ended March 31, 2021 and the year ended December 31, 2020 was as follows:

 

  Options  Weighted Average Exercise Price ($)  Weighted Average Remaining Contractual Life (Yrs.)  Aggregate Intrinsic Value ($) 
        -    
SARs outstanding at December 31, 2019  -   -   -    
Granted  127,679   2.61   4.52   97,919 
Exercised  -   -   -   - 
Forfeited or cancelled  -   -   -   - 
SARs outstanding at December 31, 2020  127,679   2.61   4.52   97,919 
Granted  -   -   -   - 
Exercised  -   -   -   - 
Forfeited or cancelled  -   -   -   - 
SARs outstanding March 31, 2021  127,679   2.61   4.27   141,330 
SARs expected to vest in the future as of March 31, 2021  118,679   2.62   4.25   - 
SARs exercisable at March 31, 2021  9,000   2.47   4.64   - 
SARs vested, exercisable, and SARs expected to vest at March 31, 2021  127,679   2.61   4.27   141,330 

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the $3.72 closing price of our common stock on March 31, 2021. All of the SARs grants have an exercise price currently below $3.72.

 

At March 31, 2021, there was $180,108 of unrecognized share-based compensation expense related to unvested SARs with a weighted average remaining recognition period of 2.23 years.

 

Warrants

 

Warrant activity for the three months ended March 31, 2021 the year ended December 31, 2020 was as follows:

 

  Warrants  Weighted Average Exercise Price ($)  Weighted Average Remaining Contractual Life (Yrs.) 
Warrants outstanding at December 31, 2019  363,728   25.60   3.12 
Granted  1,540,139   3.19   4.64 
Exercised  (22,438)  -   - 
Forfeited or cancelled  -   -   - 
Warrants outstanding at December 31, 2020  1,881,429   7.57   4.16 
Granted  412,143   4.60   3.66 
Exercised  (495,641)  2.59   - 
Forfeited or cancelled  -   -   - 
Warrants outstanding at March 31, 2021  1,797,931   8.26   3.72 

 

NOTE 6 - Subsequent Events

 

The Company performed an evaluation of subsequent events through the date of filing of these condensed financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the condensed financial statements.

 

15
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-looking statements

 

This Quarterly Report, including any documents which may be incorporated by reference into this Report, contains “Forward-Looking Statements.” All statements other than statements of historical fact are “Forward-Looking Statements” for purposes of these provisions, including but not limited to, statements regarding our expectations about development and commercialization of our technology, any projections of revenues or statements regarding our anticipated revenues or other financial items, any statements of the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All Forward-Looking Statements included in this document are made as of the date hereof and are based on information available to us as of such date. We assume no obligation to update any Forward-Looking Statement. In some cases, Forward-Looking Statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the Forward-Looking Statements contained herein are reasonable, there can be no assurance that such expectations or any of the Forward-Looking Statements will prove to be correct, and actual results could differ materially from those projected or assumed in the Forward-Looking Statements. Future financial condition and results of operations, as well as any Forward-Looking Statements are subject to inherent risks and uncertainties, including any other factors referred to in our press releases and reports filed with the Securities and Exchange Commission (“SEC”). All subsequent Forward-Looking Statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Additional factors that may have a direct bearing on our operating results are described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and elsewhere in this report.

 

Corporation Information

 

We were incorporated as Messidor Limited in Nevada on December 23, 1985 and changed our name to Framewaves Inc. in 2001. On September 27, 2010, we changed our name from Framewaves Inc. to Sigma Labs, Inc. We commenced our current business operations in 2010.

 

Our principal executive offices are located at 3900 Paseo del Sol, Santa Fe, New Mexico 87507, and our telephone number is (505) 438-2576. Our website address is www.sigmalabsinc.com. The Company’s annual reports, quarterly reports, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), and other information related to the Company, are available, free of charge, on that website as soon as we electronically file those documents with, or otherwise furnish them to, the SEC. The Company’s website and the information contained therein, or connected thereto, are not and are not intended to be incorporated into this Quarterly Report on Form 10-Q.

 

16
 

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the accompanying consolidated financial statements and related notes. These estimates and assumptions have a significant impact on our consolidated financial statements. Actual results could differ materially from those estimates. Critical accounting policies are those that require the most subjective and complex judgments, often employing the use of estimates about the effect of matters that are inherently uncertain. Our significant accounting policies are disclosed in Note 1 to the Financial Statements included in this Quarterly Report on Form 10-Q. However, we do not believe that there are any alternative methods of accounting for our operations that would have a material effect on our financial statements.

 

Results of Operations

 

We generate revenues through PrintRite3D® hardware and CAI software licensing of our PrintRite3D® technology to customers that seek to improve their manufacturing production processes, and through ongoing annual software upgrades and maintenance fees. Additionally, we generate revenues from our contract manufacturing activities in metal additive manufacturing (AM). Our ability to generate revenues in the future will depend on our ability to further commercialize and increase market presence of our PrintRite3D® technologies, and it will depend on whether key prospective customers continue to move from AM metal prototyping to production.

 

During the three months ended March 31, 2021, we recognized revenue of $458,140, as compared to $221,730 in revenue recognized during the same period in 2020, an increase of $236,410. The increase is primarily due to increased PrintRite3D® unit sales of $277,300 in the first quarter of 2021, partially offset by lower revenues of $52,200 from our Rapid Test and Evaluation (“RTE”) program.

 

Our Cost of Revenue for the three months ended March 31, 2021 and 2020 was $128,331 and $244,703, respectively, a decrease of $116,372. The decreased cost is primarily attributable to a credit of $43,952 related to a customer exchange of a PrintRite3D unit sold in December 2020, lower build costs as a result of engineering enhancements of our PrintRite3D units, and lower costs of supporting legacy RTE programs.

 

Sigma’s total operating expenses for the three months ended March 31, 2021 were $1,781,404 as compared to $1,559,641 for the same period in 2020, an increase of $221,763.

 

Salary and Benefits costs were $847,171 for the three months ended March 31, 2021 compared to $652,197 for the same period in 2020, an increase of $194,974. This increase is due to an increase of nine full-time equivalent employees between the two periods.

 

Stock-based Compensation was $117,477 for the three months ended March 31, 2021 compared to $154,171 for the same period in 2020, a $36,694, or 24%, decrease. This decrease is primarily a result of stock options granted to our CEO vesting in the first quarter of 2020 with no such vesting in the first quarter of 2021, partially offset by stock option grants to four new employees during the three months ended March 31, 2021.

 

Operating and Research and Development expenditures of $196,340 were incurred during the three months ended March 31, 2021 compared to $53,689 in the same period of 2020, a $142,651 increase. The increase is due to development costs incurred in connection with PrintRite3D version 7.0 of $48,171, purchases of lab supplies of $36,474, of which metal powder purchases totaled $14,470, write-off of $36,111 in obsolete inventory, and $20,000 incurred in connection with a simulation project.

 

Investor & Public Relations expenses of $108,341 were incurred during the three months ended March 31, 2021, as compared to $215,441 incurred during the same period in 2020. The decrease of $107,100 is primarily due to a decrease in trade show expenses of $29,902, lower advertising expenses of $50,583, and $22,165 in expenses incurred in the first quarter of 2020 in connection with a special meeting of shareholders.

 

17
 

 

Organization costs incurred in the three months ended March 31, 2021 were $77,616 compared to $49,444 incurred during the same period in 2020. The increase of $28,172 is due to an increase in non-employee director’s compensation of $44,958, partially offset by lower shareholder’s services expenses of $16,786.

 

Legal & Professional fees incurred in the three months ended March 31, 2021 were $176,847 compared to $184,891 incurred during the same period in 2020, a decrease of $8,044. This decrease is primarily a result of a decrease in legal expenses of $77,339 due to expenses incurred during the first quarter of 2020 in connection with our January 2020 private offering, Nasdaq related matters, and our February 27, 2020 reverse stock split. This decrease was partially offset by increased recruiting expenses of $26,667 related to new hires, an increase in consulting expenses of $33,310, and increases in accounting and IT support expenses of $3,031 and $3,500 respectively.

 

Office expenses for the three months ended March 31, 2021 totaled $148,225 as compared to $147,747 for the same period in 2020. Increases in payroll service fees of $7,317, postage & shipping of $11,109, office supplies of $20,888, dues & subscriptions of $7,586, and other miscellaneous expense increases of $3,805 were offset by a decrease in travel expenses of $49,398.

 

Other operating expenses were $86,356 for the three months ended March 31, 2021, as compared to $84,049 for the same period in 2020. The increase is primarily due to an increase in our insurance policy premiums for 2021 of $10,376, mostly offset by lower bank service fees and SEC filing fees during the period.

 

In the three months ended March 31, 2021, our net other income & expense was net income of $800,936 compared to net other expense of $971 in 2020. The 2021 net positive contribution is primarily due to an unrealized gain of $802,285 from the March 31, 2021 revaluation of the derivative liability resulting from our private placement of warrants to purchase 2,190,000 shares of common stock in the first quarter of 2021.

 

Sigma’s net loss applicable to common stockholders for the three months ended March 31, 2021 totaled $711,567 as compared to $1,898,832 for the same period of 2020, a $1,187,265 decrease. The first quarter 2021 net operating loss contributed $131,019 to the loss decrease, the increase in other income contributed $801,907, and a decrease in preferred dividends contributed $254,339.

 

Liquidity and Capital Resources

 

As of March 31, 2021, we had $16,843,201 in cash and working capital of $12,634,299, as compared with $3,700,814 in cash and working capital of $ 4,332,053 as of December 31, 2020.

 

Our major sources of funding have been proceeds from public and private offerings of our equity securities (both common stock and preferred stock), and from warrant exercises.

 

On March 26, 2021, the Company closed a public offering of its securities in which it issued 2,190,000 shares of common stock at $4.445 per share, resulting in net proceeds to the Company of approximately $8,736,487 after deducting placement agent commissions and other offering costs payable by the Company. Pursuant to the Purchase Agreement, the purchasers severally agreed to vote the shares of common stock purchased under the Purchase Agreement in favor of any resolution presented to the stockholders of the Company for the purpose of obtaining approval of an increase in the authorized shares of the Company’s Common Stock from 12,000,000 to 24,000,000 shares (“Stockholder Approval”). In a concurrent private placement under the Purchase Agreement, the Company issued to the purchasers warrants to purchase an aggregate of 2,190,000 shares of Common Stock at an exercise price of $4.32 per share. Each Warrant will be exercisable commencing on the date the Company obtains Stockholder Approval and will expire two years after the initial exercise date.

 

On January 12, 2021, the Company closed a public offering of common stock in which it issued 1,711,783 shares of common stock at $3.00 per share, resulting in net proceeds of approximately $4,532,445 after deducting commissions and other offering expenses payable by the Company.

 

During the first quarter of 2021, the Company received net cash proceeds of $1,136,010 from the exercise of outstanding warrants.

 

We believe that our existing cash on hand will be sufficient to fund our anticipated operating costs and capital expenditure requirements through 2022. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect.

 

Because of the numerous risks and uncertainties associated with the research, development, and commercialization of our products, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements will depend on many factors, including:

 

 The cost of expending, maintaining, and enforcing our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
 The effect of competing technological and market developments;
 The revenue from the sales of our existing and future products; and
 The cost of operating as a public company.

 

During 2021, we expect to sustain our operations and our commercialization and marketing efforts with our cash reserves and revenues generated from sales of our PrintRite3D® technology. We expect that continued enhancements of our IPQA®-enabled PrintRite3D® technology will enable us to further commercialize this technology into the AM metal market in 2021. To support the commercialization of our PrintRite3D® technology, we plan to continue funding our development activities and operating expenses by licensing our PrintRite3D® systems and supporting field services, as applicable, and providing PrintRite3D®-enabled engineering consulting services concerning our areas of expertise (materials and manufacturing quality assurance and process control technologies).

 

The outbreak of the novel coronavirus (COVID-19) has evolved into a global pandemic. The spread of the coronavirus, which has caused a broad impact globally, including restrictions on travel and quarantine policies put in place by businesses and governments, may have a material economic effect on our business. To-date, the outbreak has not had a material adverse impact on our operations, though we have experienced delays in certain customer purchase orders. While the Company believes that such purchase orders will ultimately be realized, it is impossible to predict the timing. Further, the future impact of the outbreak is highly uncertain and cannot be predicted and there is no assurance that the outbreak will not have a material adverse impact on our business and the future results of the Company. However, due to the need to have more flexibility in supply chains with the ability to respond quickly to shortages in parts or products, we believe that the crisis will eventually accelerate the adoption of 3D printing, which would be a positive trend for the Company.

 

18
 

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities during the three months ended March 31, 2021 decreased to $1,240,586 from $1,525,696 during the same period in 2020, a $285,110 decrease. Contributing to this decrease were decreases in net loss of $932,926, accounts receivable of $7,397, and deferred revenue of $43,790, and increases in depreciation and amortization of $5,019, total stock-based compensation of $16,140, accounts payable and accrued expenses of $325,706 and long-term stock appreciation rights expense of $45,184. These decreases in cash usage were partially offset by the unrealized gain on the derivative liability of $802,285 and increases in inventory and prepaid expenses of $181,044 and $107,724 respectively.

 

Net Cash Used in Investing Activities

 

Net cash used by investing activities during the three months ended March 31, 2021 was $21,969, which compares to $50,529 of cash used by investing activities during the same period of 2020, a decrease of $28,560. The decrease results from lower purchases of fixed assets and lower patent costs during the first quarter of 2021.

 

Net Cash Provided by Financing Activities

 

Cash provided by financing activities during the three months ended March 31, 2021 increased to $14,404,942 from $2,120,324 during the same period in 2020 due to the receipt of $14,869,899 of proceeds less $1,600,967 of offering costs in connection with our January and March 2021 public and private offerings. The exercise of outstanding warrants during the three months ended March 31, 2021 provided an additional $1,136,010 in cash proceeds. Cash provided by financing activities during the same period in 2020 resulted from the receipt of $2,100,000 in proceeds less $428,876 of offering costs in connection with our January 2020 private offering, partially offset by the payment of the remaining outstanding principal balance on our convertible note payable of $50,000.

 

Our ability to continue to fund our liquidity and working capital needs will be dependent upon the success of our efforts to generate revenues from existing and future PrintRite3D®-proof-of-concept contracts, follow-on contracts resulting from successful proof-of-concept engagements, possible strategic partnerships, and by obtaining additional capital from the sale of securities or by borrowing funds from lenders to fulfill our business plans. If we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. There is no assurance that we will be successful in obtaining additional funding. The Company is unable to predict the effect that the COVID-19 outbreak may have on its access to the financing markets. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations.

 

We have no credit lines as of April 22, 2021, nor have we ever had a credit line since our inception.

 

Inflation and changing prices have had no effect on our continuing operations over our two most recent fiscal years.

 

We have no off-balance sheet arrangements as defined in Item 303(a) of Regulation S-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of disclosure controls and procedures and changes in internal controls over financial reporting.

 

Rule 13a-15(e) under the Exchange Act defines the term “disclosure controls and procedures” as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our management, with the participation of our Chief Executive Officer, and our Principal Financial and Accounting Officer, as of the end of the period covered by this quarterly report, our management concluded that our disclosure controls and procedures are effective at a reasonable assurance level in ensuring that information required to be disclosed by us in our reports is recorded, processed, summarized and reported within the required time periods. In addition, no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) occurred during the three months ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

19
 

 

PART II

 

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

Not applicable.

 

ITEM 1A. RISK FACTORS.

 

You should consider the “Risk Factors” included under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 24, 2021.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None

 

20
 

 

ITEM 6. EXHIBITS.

 

1.1Underwriting Agreement, dated January 8, 2021, by and among Sigma Labs, Inc. and H.C. Wainwright & Co., LLC, as the representative for the underwriters named therein (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).
  
4.1Form of Underwriter Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).
  
4.2Form of Warrant to Purchase Common Stock (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).
  
4.3Form of Warrant to Purchase Common Stock (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed March 30, 2021, and incorporated herein by reference).
  
4.4Form of Placement Agent Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed March 30, 2021, and incorporated herein by reference).
  
10.1Form of Waiver (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).
  
10.2Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 30, 2021, and incorporated herein by reference).
  
31.1Rule 13a-14(a) Certification of Principal Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
  
31.2Rule 13a-14(a) Certification of Principal Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
  
32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***
  
101.INSXBRL Instance Document.
101.SCHXBRL Schema Document.
101.CALXBRL Calculation Linkbase Document.
101.DEFXBRL Definition Linkbase Document.
101.LABXBRL Labels Linkbase Document.
101.PREXBRL Presentation Linkbase Document.

 

** Filed herewith.

*** Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

21
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 SIGMA LABS, INC.
   
April 22, 2021By:/s/ Mark K. Ruport
  Mark K. Ruport
  President and Chief Executive Officer (Principal Executive Officer)
   
April 22, 2021By:/s/ Frank Orzechowski
  Frank Orzechowski
  Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

 

22